New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
07:03 EDTENDP, BDSIBioDelivery Sciences announces Buprenorphine study to be locked by Endo Health
The database for the BEMA Buprenorphine Phase 3 clinical study in opioid naive patients with chronic pain is expected to be locked shortly by BDSI's partner, Endo Pharmaceuticals. This event is expected to trigger a $10M milestone payment from Endo per the licensing and development agreement signed in January 2012. In addition, based on recruitment rates in a second Phase 3 clinical study of BEMA Buprenorphine in an opioid experienced patient group, the database for this trial is anticipated to be locked by mid-2014, with results following shortly thereafter.
News For BDSI;ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 20, 2015
08:09 EDTENDPBioSpecifics announces approval of Xiaflex in Japan
Subscribe for More Information
July 17, 2015
10:05 EDTENDPOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:38 EDTENDPLeerink puts 25% odds on Teva, Mylan deal within 12 months
Subscribe for More Information
06:43 EDTENDPEndo upgraded to Top Pick from Outperform at RBC Capital
Subscribe for More Information
July 16, 2015
11:36 EDTBDSIBioDelivery Sciences management to meet with FBR Capital
Meetings to be held in Minneapolis on July 22 and in Dallas on July 23 hosted by FBR Capital.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use